RecruitingTriple-Negative Breast Cancer (TNBC)
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Eligible age
18–75 yrs
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with a PD-1 monoclonal antibody in patients with PD-L1-positive, previously untreated, inoperable locally advanced or recurrent metastatic triple-negative breast cancer.
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
You may qualify if…
- ✓ 1. Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
- ✓ 2. Female patients aged 18 to 75 years;
- ✓ 3. Expected survival time ≥ 3 months;
- ✓ 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- ✓ 5. Pathologically confirmed recurrent or metastatic triple-negative breast cancer;
- ✓ 6. Confirmed PD-L1 expression positivity by central laboratory testing;
- ✓ 7. No prior systemic anti-tumor therapy in the advanced/recurrent or metastatic setting;
- ✓ 8. Agree to provide archived tumor tissue specimens (surgical specimens) or fresh tissue samples from primary or metastatic lesions obtained within 3 years;
You may not qualify if…
- ✕ 1. Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose;
- ✕ 2. Prior exposure to ADC drugs with topoisomerase I inhibitor payload;
- ✕ 3. Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1);
- ✕ 4. Use of immunomodulators within 14 days before the first study drug dose;
- ✕ 5. History of severe cardiac or cerebrovascular disease;
- ✕ 6. Receiving chronic systemic corticosteroids at \>10 mg/day prednisone before the first dose;
- ✕ 7. Active autoimmune or inflammatory disease;
- ✕ 8. Any thrombotic event within 6 months before randomization;
Source: ClinicalTrials.gov · NCT07729956 · last updated 2026-09-30